ATC Group: L04AC19 Satralizumab

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L04AC19 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L04 Immunosuppressants
3 L04A Immunosuppressants
4 L04AC Interleukin inhibitors
5 L04AC19

Active ingredients in L04AC19

Active Ingredient Description
Satralizumab

Satralizumab is a recombinant humanised immunoglobuline G2 (IgG2) monoclonal antibody (mAb) that binds to soluble and membrane-bound human IL-6 receptor (IL-6R) and thereby prevents IL-6 downstream signalling through these receptors.

Related product monographs

Title Information Source Document Type  
ENSPRYNG Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
ENSPRYNG Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Canada (CA)

Ecuador (EC)

Estonia (EE)

Finland (FI)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Poland (PL)

Romania (RO)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.